Skip to main content
SpringerLink
Log in

Phase II trial of gallium nitrate in previously treated patients with small cell lung cancer

  • Published:
Investigational New Drugs Aims and scope Submit manuscript

Abstract

Gallium nitrate is a group IIIa metal that was found to be active in animal species [1]. Gallium nitrate exerts its antitumor effects via a transferrin binding mechanism [2]. This agent is of interest in small cell lung cancer since 26 of 27 small cell carcinoma cell lines tested had increased levels of transferrin receptors [3]. In a phase I study using a continuous infusion, the dose limiting toxicity was nausea when gallium nitrate was given at doses of 400 mg/m2/day. Other effects included elevations of serum creatinine, hypocalcemia, hypomagnesemia, decreased hearing and paresthesias [4]. Activity has been seen in pretreated patients with malignant lymphoma, bladder carcinoma and small numbers of patients with small cell lung carcinoma [4, 5]. To determine the activity of continuous infusion gallium nitrate, this phase II trial was undertaken in patients with small cell lung cancer previously treated with chemotherapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Hart N, Smith C, Vancey S, et al.: Toxicity and antitumor activity of gallium nitrate and periodically related metal salts. J Natl Cancer Inst 47:1121–7, 1971

    PubMed  Google Scholar 

  2. Chitamber C, Massey E, Seligman P: Regulation of transferrin receptor expression on human leukemic cells during proliferation and induction of differentiation. Effects of gallium and dimethylsulfoxide. J Clin Invest 72:1314–25, 1983

    PubMed  Google Scholar 

  3. Carney D. IASLC Workshop on Small Cell Lung Cancer, Gleneagles, Scotland. 1984

    Google Scholar 

  4. Warrell R, Coonley C, Straus D, et al.: Treatment of patients with advanced malignant lymphomas using gallium nitrate administered as a seven day continuous infusion. Cancer 51:1982–7, 1983

    PubMed  Google Scholar 

  5. National Cancer Institute, Investigator's Update: Gallium Nitrate, 1983

Download references

Author information

Authors and Affiliations

  1. Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine and Department of Medical Imaging, Memorial Sloan-Kettering Cancer and Cornell University Medical College, New York, NY, USA

    Jose Baselga, Mark G. Kris, Howard I. Scher, Mary Phillips & Robert T. Heelan

Authors
  1. Jose Baselga
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mark G. Kris
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Howard I. Scher
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Mary Phillips
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Robert T. Heelan
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Baselga, J., Kris, M.G., Scher, H.I. et al. Phase II trial of gallium nitrate in previously treated patients with small cell lung cancer. Invest New Drugs 11, 85–86 (1993). https://doi.org/10.1007/BF00873918

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00873918

Key words

Search

Navigation